The Administrative Core will provide management services to each of the Projects and Cores in this Program. The Core will provide financial, administrative, and clerical services for the PI, the Co-Pl, Project Leaders, and Core Leaders for all grant-related activities. These activities include preparation of this competing renewal, non-competing renewals including progress reports, preparation of budgets, communication with the NIH regarding renewals and all financial interactions, and assurance that the labs supported by this Program are in full compliance with all institutional, state and federal regulations. Core A will also coordinate and schedule all meetings related to the function of the Program, including monthly meetings of all Project and Core leaders, and members of their respective laboratories, as well as annual meetings of the Internal and External Advisory Boards. Core A will also coordinate efforts with Dr. Armstrong, the sole off-site investigator, to travel to meetings or teleconference. Dr. Ebert is the PI and Director of this Core, and will serve as the overall scientific director and chief administrator. Dr. Griffin is the Co-Pl and will assist in these operations, particularly with regard to clinical programs, core facilities, and samples at the DFCI. He will assist Dr. Ebert in monitoring protocol performance and will assist in protocol development. Chanel Logan is a highly skilled administrator with experience in management of fiscal and administrative matters for large program project grants. She will serve as Administrative Facilitator, manage budgets between participating institutions, prepare reports including non-competing renewals, interface with the financial officers of each participating institution in the Program, and serve as an interface between these groups and the NIH. In addition, the Administrative Core will assure compliance and appropriate regulations regarding experimentation with human subjects, (including gender and minority participation) and vertebrate animals.

Public Health Relevance

The Administrative Core will provide management services to each of the Projects and Cores in this Program. The Core will provide financial, administrative, and clerical services for the Pl, the Co-Pl, Project Leaders, and Core Leaders for all grant-related activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-20
Application #
9556988
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
Patel, Sanjay S; Kuo, Frank C; Gibson, Christopher J et al. (2018) High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood 131:2816-2825
Montero, Joan; Letai, Antony (2018) Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ 25:56-64
DeAngelo, Daniel J; Brunner, Andrew M; Werner, Lillian et al. (2018) A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol 93:254-261
Fink, Emma C; McConkey, Marie; Adams, Dylan N et al. (2018) CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132:1535-1544
Wroblewski, Mark; Scheller-Wendorff, Marina; Udonta, Florian et al. (2018) BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica 103:939-948
Konopleva, Marina; Letai, Anthony (2018) BCL-2 inhibition in AML: an unexpected bonus? Blood 132:1007-1012
Donovan, Katherine A; An, Jian; Nowak, Rados?aw P et al. (2018) Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife 7:
Lee, J Scott; Roberts, Andrew; Juarez, Dennis et al. (2018) Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med 10:
Liu, Bee Hui; Jobichen, Chacko; Chia, C S Brian et al. (2018) Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide. Proc Natl Acad Sci U S A 115:E7119-E7128
Kahn, Josephine D; Miller, Peter G; Silver, Alexander J et al. (2018) PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood 132:1095-1105

Showing the most recent 10 out of 376 publications